3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Leukemia, Myeloid, Acute
213
Myelodysplastic Syndromes
82
Leukemia
44
Leukemia, Myelomonocytic, Chronic
35
Recurrence
16
Myeloproliferative Disorders
15
Neoplasm, Residual
10
Lymphoma, T-Cell, Peripheral
10
Leukemia, Biphenotypic, Acute
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Myelodysplastic-Myeloproliferative Diseases
7
Lymphoma, Large B-Cell, Diffuse
7
Anemia, Refractory, with Excess of Blasts
7
Primary Myelofibrosis
6
Lymphoma, Non-Hodgkin
6
Hodgkin Disease
6
Congenital Abnormalities
6
Lymphoma, T-Cell
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Leukemia, Monocytic, Acute
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Hematologic Neoplasms
5
Polycythemia Vera
4
Pancreatic Neoplasms
4
Multiple Myeloma
4
Lymphoma, Follicular
4
Lymphoma, Extranodal NK-T-Cell
4
Leukemia, Myeloid
4
Interventions
pembrolizumab
1
ibrutinib
1
Watchful Waiting
1
Sertraline
1
Quality of Life
1
Electrocardiography
1
Clinical Laboratory Techniques
1
Bone Marrow Transplantation
1
Bone Marrow Examination
1
Biopsy
1
Azacitidine
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Bone Marrow Diseases
×
Azacitidine
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled